CinCor Pharma, Inc.
CINC · NASDAQ
9/30/2022 | 6/30/2022 | 3/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 1.53 | 1.02 | 0.20 | -0.02 |
| FCF Yield | -1.13% | -2.75% | -3.02% | -1.95% |
| EV / EBITDA | -53.11 | -27.30 | -30.78 | -14.66 |
| Quality | ||||
| ROIC | -4.03% | -7.03% | -4.34% | -20.26% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.72 | 0.93 | 1.06 | 0.38 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 22.38% | -10.39% | -60.65% | -76.71% |
| Safety | ||||
| Net Debt / EBITDA | 14.85 | 5.98 | 12.01 | 4.66 |
| Interest Coverage | -17.56 | -76.98 | -266.37 | -1,836.15 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |